TY - JOUR
T1 - Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk
T2 - An exploratory genotype-environment interaction study
AU - Quiñones, Luis A.
AU - Irarrázabal, Carlos E.
AU - Rojas, Claudio R.
AU - Orellana, Cristian E.
AU - Acevedo, Cristian
AU - Huidobro, Christian
AU - Varela, Nelson E.
AU - Cáceres, Dante D.
PY - 2006/5
Y1 - 2006/5
N2 - Aim: To assess the role of several genetic factors in combination with an environmental factor as modulators of prostate cancer risk. We focus on allele variants of low-penetrance genes associated with cell control, the detoxification processes and smoking. Methods: In a case-control study we compared people carrying p53cd72 Pro allele, CYP1A1 M1 allele and GSTM1 null genotypes with their prostate cancer risk. Results: The joint risk for smokers carrying Pro* and M1*, Pro* and GSTM1 null or GSTM1 null and CYP1A1 M1* variants was significantly higher (odds ratio [OR]: 13.13, 95% confidence interval [CI]: 2.41-71.36; OR: 3.97, 95% CI: 1.13-13.95 and OR: 6.87, 95% CI: 1.68-27.97, respectively) compared with that for the reference group, and for non-smokers was not significant. OR for combinations among p53cd72, GSTM1 and CYP1A1 M1 in smokers were positively and significantly associated with prostate cancer risk compared with non-smokers and compared with the putative lowest risk group (OR: 8.87, 95% CI: 1.25-62.71). Conclusion: Our results suggest that a combination of p53cd72, CYP1A1, GSTM1 alleles and smoking plays a significant role in modified prostate cancer risk on the study population, which means that smokers carrying susceptible genotypes might have a significantly higher risk than those carrying non-susceptible genotypes.
AB - Aim: To assess the role of several genetic factors in combination with an environmental factor as modulators of prostate cancer risk. We focus on allele variants of low-penetrance genes associated with cell control, the detoxification processes and smoking. Methods: In a case-control study we compared people carrying p53cd72 Pro allele, CYP1A1 M1 allele and GSTM1 null genotypes with their prostate cancer risk. Results: The joint risk for smokers carrying Pro* and M1*, Pro* and GSTM1 null or GSTM1 null and CYP1A1 M1* variants was significantly higher (odds ratio [OR]: 13.13, 95% confidence interval [CI]: 2.41-71.36; OR: 3.97, 95% CI: 1.13-13.95 and OR: 6.87, 95% CI: 1.68-27.97, respectively) compared with that for the reference group, and for non-smokers was not significant. OR for combinations among p53cd72, GSTM1 and CYP1A1 M1 in smokers were positively and significantly associated with prostate cancer risk compared with non-smokers and compared with the putative lowest risk group (OR: 8.87, 95% CI: 1.25-62.71). Conclusion: Our results suggest that a combination of p53cd72, CYP1A1, GSTM1 alleles and smoking plays a significant role in modified prostate cancer risk on the study population, which means that smokers carrying susceptible genotypes might have a significantly higher risk than those carrying non-susceptible genotypes.
KW - CYP1A1
KW - GSTM1
KW - Genetic polymorphism
KW - Prostate cancer
KW - Risk
KW - Smoking
KW - p53cd72
UR - http://www.scopus.com/inward/record.url?scp=33646034587&partnerID=8YFLogxK
U2 - 10.1111/j.1745-7262.2006.00135.x
DO - 10.1111/j.1745-7262.2006.00135.x
M3 - Article
C2 - 16625286
AN - SCOPUS:33646034587
SN - 1008-682X
VL - 8
SP - 349
EP - 355
JO - Asian Journal of Andrology
JF - Asian Journal of Andrology
IS - 3
ER -
